Meet the scientists, doctors, founders, practitioners and familiar faces shaping how we live longer.
Sindhya Valloppillil is an entrepreneur, Fortune journalist, and Founder of Skin Dossier, a precision skin-health SaaS company. Covering longevity, health tech, and venture capital, she blends investigative reporting with startup and corporate leadership, and is a Venture Partner at NextGen Venture Partners.
GLP‑1 drugs have surged as weight‑loss treatments, but their broader impact on metabolic health, cardiovascular risk and system-wide costs is still emerging. This session explores what GLP‑1s agonists could mean for clinical practice, insurers, employers and consumers, and how these therapies might fit into wider prevention and care strategies as evidence and appetite builds.
GLP-1 medications are reshaping discussions on weight, metabolism and disease prevention. This panel explores the science, benefits and limitations of GLP-1s and what their rise means for long term health strategies. The science is transformative and whether it’s for weight loss or longevity, this session will arm you with answers to many open questions.
Join the priority list to be first to hear about speakers, experiences and ticket releases, plus get 15% off Early Bird tickets.
You’re in.
Thanks for joining The Longevity Show community.
As a thank you, here’s 15% off your ticket:Code: WELCOME15
Use it at checkout and we’ll see you at Tobacco Dock.
